Reference

The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation

The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation. Ziemniak, J. A.; Allison, N.; Boppana, V. K.; Dubb, J.; Stote, R. (Smith Kline and French Lab., Dep. Drug Metab., Swedeland, PA 19479, USA). Clin. Pharmacol. Ther. (St. Louis), 41(3), 275-81 (English) 1987. CODEN: CLPTAT. 87549-38-0 and 67227-56-9 are also in the experiment. ISSN: 0009-9236. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In normal human subjects, concomitant dosing of fenoldopam mesylate (I) [67227-57-0] with acetaminophen [103-90-2] resulted in increases in peak fenoldopam plasma concn. and area under the curve (AUC) after both single and chronic acetaminophen dosing. Decreases in peak plasma concns. and AUC for fenoldopam's sulfated metabolites were seen in both studies. These findings indicate a metabolic basis for the interaction between fenoldopam and acetaminophen, presumably through a competition for inorg. sulfate. .

Synergistic antihypertensive compositions containing benzazepines and b-adrenergic blockers

Synergistic antihypertensive compositions containing benzazepines and b-adrenergic blockers. Ackerman, Dennis Marvin; Berkowitz, Barry Alan; Wiebelhaus, Virgil Daniel (SmithKline Beckman Corp., USA). S. 72912-26-6 and 86695-26-3 are also occured in this study. African ZA 8209004 A 28 Sep 1983, 23 pp. (English). (South Rica). CODEN: SFXXAB. ICI: A61. APPLICATION: ZA 82-9004 7 Dec 1982. PRIORITY: DE 81-8111025 8 Dec 1981. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Synergistic antihypertensive compns. contain a renal dopaminergic benzazepine (I, X = Cl, F, or Me) or its salts or prodrug derivs. which have sp. renal vasodilating activity after oral or parenteral administration but which do not, by themselves elevate glomerular filtration, combined with 31 b-adrenergic blocking agent; the compns. increase the glomerular filtration rate, inhibit renin release, improve kidney function and have improved antihypertensive effect beyond that of simply adding the effects of the components. Thus, a tablet compn. was prepd. contg. 6-chloro-7,8-dihydroxy-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-b enzazepine methanesulfonate (I, X = Cl;.MeSO3H) [67227-57-0] 100, propranolol-HCl [318-98-9] 40, sucrose 25, CaSO4.2H2O 50, talc 5, stearic acid 3, and starch 10 mg. Capsule formulations contg. the 2 active components were also prepd. The synergistic renal effect of the b-blocker-I combination on blood flow, Na+ excretion, glomerular filtration rate, and release of renin was shown in dogs. .